drugset / Trial / NCT00078910

Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

NCT00078910

Phase 2 Completed 130 enrolled National Cancer Institute (NCI)
Non-randomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as exisulind, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well neoadjuvant exisulind works in treating patients who are undergoing radical prostatectomy for stage II or stage III prostate cancer.

Timeline

Start
2003-08
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Exisulind Small molecule Oral

Indications